z-logo
Premium
Kinetic expression of platelet endothelial cell adhesion molecule‐1 (PECAM‐1/CD31) during embryonic stem cell differentiation
Author(s) -
Li Zong Jin,
Wang Zack Z.,
Zheng Yi Zhou,
Xu Bin,
Yang Ren Chi,
Scadden David T.,
Han Zhong Chao
Publication year - 2005
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.20436
Subject(s) - vasculogenesis , cd31 , angiogenesis , embryonic stem cell , microbiology and biotechnology , endothelial stem cell , biology , gene isoform , stem cell , cell adhesion molecule , cellular differentiation , embryoid body , cell adhesion , cell , adult stem cell , progenitor cell , in vitro , cancer research , genetics , gene
Platelet endothelial cell adhesion molecule‐1 (PECAM‐1/CD31) is widely used as a marker during vasculogenesis and angiogenesis from embryonic stem (ES) cells. However, the expression of PECAM‐1 isoforms in ES cells has not been determined. The present study was designed to determine the role of PECAM‐1 isoforms during in vitro endothelial differentiation of ES cells. It was found that undifferentiated ES cells expressed high level of PECAM‐1, which primarily located at cell–cell junction, but the expression of PECAM‐1 was sharply down‐regulated during early ES cell differentiation. In addition, undifferentiated ES cells were found the expressed all eight known alternatively spliced PECAM‐1 isoforms, among them the expression of PECAM‐1 isoforms lacking exon 15 or 14&15 was predominant. Quantitative analysis revealed a significant increase in the expression of PECAM‐1 isoform lacking exon 12&14&15 as vascular development of ES cells. These results indicate a constitutive expression of PECAM‐1 in undifferentiated murine ES cells and suggest a developmental role of PECAM‐1 isoform changes during vasculogenesis and angiogenesis. © 2005 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here